Country's largest drug maker Ranbaxy today said its pharmaceutical products, including the HIV/AIDS drugs, which it produces from two of its plants located in Dewas and Ponta Sahib in the country, are safe and is committed to working with US FDA.
"Ranbaxy is confident that all its pharmaceutical products are safe and effective, including the HIV/AIDs drugs it supplies to Africa through various aid programmes, including PEPFAR," the company said in a statement.
The company was reacting to US President's Emergency Plan for AIDS Relief (PEPFAR) decision to suspend funding for three generic HIV/AIDS drugs till the US Food and Drug Administration's gives it a clean chit.
PEPFAR yesterday said it would suspend funding for the HIV/AIDS drugs to Ranbaxy till the time issues raised by the US FDA on manufacturing deficiencies in company's two plants located at Dewas and Ponta Sahib, where these drugs are produced, were resolved.
"Ranbaxy is committed to working with Chairman Dingell and Food and Drug Administration (FDA) to put these matters to rest and continue and expand its important place in providing safe and affordable medications to US and global citizens," the company said.
Following the FDA announcement on September 16, 2008 that it would partially restrict drug imports manufactured by Ranbaxy, leaders of the US Congressional Committee on Energy and Commerce have expanded their inquiry into the FDAs handling of the case to include drugs manufactured by the company for the PEPFAR.
Ranbaxy shares were trading at Rs 279.20, down 5.74 per cent during afternoon trade on the BSE.